1.0 Background
This AusPAR describes the application by the sponsor Actelion Pharmaceuticals Ltd to register selexipag, a new chemical entity, for the treatment of subtypes of pulmonary arterial hypertension (PAH) as monotherapy or in combination with an endothelin receptor antagonist (ERA) or a phosphodiesterase type 5 (PDE5) inhibitor or in combination with ... ................
................
To fulfill the demand for quickly locating and searching documents.
It is intelligent file search solution for home and business.
Related download
- analysis of phosphodiesterase type 5 pde 5 inhibitor drugs
- phosphodiesterase type 5 inhibitors for the
- pde5 inhibitors tadalafil sildenafil vardenafil
- sponsor hearing
- title stopp start criteria for potentially
- uk
- list of tables pharmaceutical benefits scheme pbs home
- international journal of medical sciences
- attachment extract from clinical evaluation report
- basic pharmacology angelfire
Related searches
- 1 or 2 374 374 1 0 0 0 1 168 1 1 default username and password
- 1 or 3 374 374 1 0 0 0 1 168 1 1 default username and password
- 1 or 2 711 711 1 0 0 0 1 168 1 1 default username and password
- 1 or 3 711 711 1 0 0 0 1 168 1 1 default username and password
- 1 or 2 693 693 1 0 0 0 1 168 1 1 default username and password
- 1 or 3 693 693 1 0 0 0 1 168 1 1 default username and password
- 1 or 2 593 593 1 0 0 0 1 or 2dvchrbu 168 1 1 default username and password
- 1 or 3 593 593 1 0 0 0 1 or 2dvchrbu 168 1 1 default username and password
- 1 or 2 910 910 1 0 0 0 1 168 1 1 default username and password
- 1 or 3 910 910 1 0 0 0 1 168 1 1 default username and password
- 192 1 or 2 33 33 1 0 0 0 1 1 1 default username and password
- 1 or 2 364 364 1 0 0 0 1 168 1 1 admin username and password